DCA Systems HbA1c Reagent Kit
Publicado el 27 de marzo de 2024 · Inicio del retiro: 7 de febrero de 2024
Resumen
FDA registra el retiro Z-1304-2024 de dispositivos médicos de Clase II, publicado el 27 de marzo de 2024 e iniciado el 7 de febrero de 2024. Empresa responsable: Siemens Healthcare Diagnostics, Inc.; Estado: En curso; Cantidad reportada: 74,211 Kits (Expanded 2/28/24: additional 72,892 kits); Lote: Siemens Material Number: 10311134; UDI/DI: 00630414532806; Lot#: 9640093, 0645103, 0648103, 0649103, 0654103 . Expanded Lots (02/28/2024): 0637093, 0641093, 0642093, 0647103, 0653103, 0655103. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
The reason for the recall is that the Siemens DCA HbA1c Reagent Kit was confirmed to display a positive bias without alerting the user. The potential impact of the defect is that erroneous test results could be reported and potentially lead to incorrect patient management of glucose control. A positive bias may be observed with eleven HbA1c affected lots. Positive bias was observed when the performance of these five HbA1c lots was compared to NGSP pooled patient target-value assigned samples and the maximum bias observed was 19%.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Siemens Healthcare Diagnostics, Inc.
- Distribuidor
- Worldwide distribution - US Nationwide and the country of Taiwan.
- Lote
- Siemens Material Number: 10311134; UDI/DI: 00630414532806; Lot#: 9640093, 0645103, 0648103, 0649103, 0654103 . Expanded Lots (02/28/2024): 0637093, 0641093, 0642093, 0647103, 0653103, 0655103;
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAAtellica CH Revised C-Reactive Protein (RCRP); Siemens Material Number (SMN): 11537223;7 de octubre de 2026
- FDABeckman Coulter, Emit 2000 Quinidine Assay REF: OSR4Q229 Contents: R1: 2 x 23 mL;R2 2x13 mL26 de agosto de 2026
- FDASyva EMIT 2000 Quinidine Assay REF: 4Q019UL Contents: 1x28 mL, 1x14mL26 de agosto de 2026
- FDASyva Emit tox Serum Tricyclic Antidepressant Calibrator/Controls SMN 10445390 Catalog No. 7C219UL12 de agosto de 2026
- FDAAccess Total T4, REF 33800, IVD, thyroxine reagent assay.27 de marzo de 2024
- FDATENSIVE Conductive Adhesive Gel, REF 016-40160027 de marzo de 2024
Preguntas sobre este retiro
¿DCA Systems HbA1c Reagent Kit fue retirado del mercado?
Sí. FDA publicó el retiro Z-1304-2024 el 27 de marzo de 2024. Peligro reportado: The reason for the recall is that the Siemens DCA HbA1c Reagent Kit was confirmed to display a positive bias without alerting the user. The potential impact of the defect is that erroneous test results could be reported and potentially lead to incorrect patient management of glucose control. A positive bias may be observed with eleven HbA1c affected lots. Positive bias was observed when the performance of these five HbA1c lots was compared to NGSP pooled patient target-value assigned samples and the maximum bias observed was 19%.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter